Testimony set to begin in pregnancy drug case

by Denise Lavoie
The Melnick sisters, who are suing Eli Lilly and Co. alleging that a synthetic estrogen known as DES caused them all to get breast cancer, pose at their hotel in Boston, Monday evening, Jan. 7, 2013. Testimony is set to begin in their federal lawsuit against the drug maker on Tuesday Jan. 8th. From left are Francine Melnick, Andrea Andrews, Donna McNeely and Michele Fecho. (AP Photo/Charles Krupa)

(AP)—Testimony is set to begin in a federal lawsuit brought by four sisters who believe their breast cancer was caused by a drug their mother took during pregnancy in the 1950s.

The case involves a known as DES, prescribed to millions of pregnant women between the late 1930s and early 1970s to prevent miscarriages, premature births and other problems. Studies later showed the drug did not prevent miscarriages.

The Melnick sisters, who grew up in Tresckow, Penn., say they all developed breast cancer in their 40s after their mother took DES while pregnant. They say their mother did not take DES while pregnant with a fifth sister, and that sister has not developed . They are seeking unspecified damages.

Opening statements and testimony are expected Tuesday.

add to favorites email to friend print save as pdf

Related Stories

Boston lawsuit claims DES-breast cancer link

Jan 08, 2012

(AP) -- Arline MacCormack first heard about DES from her mother when she was 17. Three decades later, MacCormack believes that the drug her mother took to prevent miscarriages caused her to develop breast ...

Breast cancer prognosis runs in the family

Jun 29, 2007

The chances of developing breast cancer are to some extent inherited, but important new findings suggest survival also runs in the family. Research published in the online journal Breast Cancer Research suggests that if a w ...

Recommended for you

Protalix signs supply deal with Brazilian govt

14 hours ago

Shares of Protalix BioTherapeutics Inc. jumped in premarket trading Wednesday after the drug developer announced a deal that requires the Brazilian government to buy at least $280 million of the company's Gaucher disease ...

EU fines pharma firms over generics delay (Update)

15 hours ago

(AP)—The European Union has fined Danish pharmaceuticals multinational Lundbeck and several other producers a combined 146 million euros ($195 million) for delaying the market entry of cheaper generic alternatives ...

Investigational drug improves sleep disorder among the blind

Jun 17, 2013

An investigational new drug significantly improved a common and debilitating circadian rhythm sleep disorder that frequently affects people who are completely blind, a multicenter study finds. The results were presented Monday ...

User comments

More news stories

Validating maps of the brain's resting state

Kick back and shut your eyes. Now stop thinking. You have just put your brain into what neuroscientists call its resting state. What the brain is doing when an individual is not focused on the outside world ...

US doctors' group labels obesity a disease

(HealthDay)—In an effort to focus greater attention on the weight-gain epidemic plaguing the United States, the American Medical Association has now classified obesity as a disease.